AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24901040
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia (15 mg bupivacaine injected at L3-4)
Trial: 22910171
Drug: Oseltamivir-zanamivir combination
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oseltamivir-zanamivir combination therapy
Trial: 22910171
Drug: Zanamivir monotherapy
RxNorm normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanamivir monotherapy
Trial: 17284743
Drug: Labeled heme
RxNorm normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labeled heme iron (2 mg as hemoglobin)
Trial: 17284743
Drug: Labeled heme
RxNorm normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labeled heme iron (4 mg as hemoglobin)
Trial: 17284743
Drug: Labeled heme
RxNorm normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labeled heme iron (8 mg as hemoglobin)
Trial: 17284743
Drug: Zinc intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc intake (1 mg)
Trial: 17284743
Drug: Zinc intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc intake (9 mg)
Trial: 7741186
Drug: Budesonide (Pulmicort;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (Pulmicort; 200 micrograms twice daily)
Trial: 7741186
Drug: Long-acting theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting theophylline (Theodur; 200 mg twice daily)
Trial: 7741186
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Budesonide + Theophylline)
Trial: 7741186
Drug: Budesonide and
RxNorm normalized name: Budesonide and formoterol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide and Combination therapy
Trial: 7234840
Drug: Cimetidine and
RxNorm normalized name: Cimetidine and sodium alginate only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine and Antacids (for isolated antral ulcer)
Trial: 7234840
Drug: Antacids (for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacids (for primary duodenal ulcer)
Trial: 7234840
Drug: Secondary ulcer
RxNorm normalized name: Secondary potassium phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary ulcer treatment
Trial: 19685114
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg bupivacaine plus 25 microg fentanyl (group BF)
Trial: 11532560
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of signs
Trial: 9364289
Drug: gamma-linolenic acid
RxNorm normalized name: gamma-linolenic acid
DrugBank: Gamolenic acid (DB13854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gamma-linolenic acid (C18:3 n‐6) at a dosage of 274 mg twice a day
Trial: 3296962
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g carbohydrate supplement
Trial: 3296962
Drug: No carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No carbohydrate supplement (control group)
Trial: 3296962
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily insulin
Trial: 3296962
Drug: Glycosylated haemoglobin
RxNorm normalized name: Glycosylated haemoglobin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycosylated haemoglobin concentration in children on twice daily insulin with nocturnal hypoglycaemia
Trial: 25764960
Drug: Cost per
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost per DFU treatment for ECM
Trial: 25764960
Drug: Cost per
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost per DFU treatment for HFDS
Trial: 25764960
Drug: Total treatment
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total treatment costs comparison
Trial: 8906009
Drug: Yuzpe regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yuzpe regimen (0.5 mg levonorgestrel and 0.1 mg ethinylestradiol)
Trial: 8906009
Drug: Danazol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (600 mg orally, repeated after 12 hours)
Trial: 1925837
Drug: Prazosin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (2 mg, increased to 4, 10, and 20 mg)
Trial: 1925837
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 mg, increased to 10, 20, and 40 mg)
Trial: 6626435
Drug: Dipyridamole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (2 or 20 micrograms/ml) in vitro
Trial: 30558054
Drug: Change in
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change in CAP after treatment
Trial: 27651323
Drug: Erdosteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdosteine (600 mg/day)
Trial: 24156617
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg ethinyl estradiol (EE) and 100 μg levonorgestrel (LNG) OCs
Trial: 24156617
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg EE and 150 μg LNG OCs
Trial: 18841784
Drug: Teacher tablets
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Teacher tablets for 7 days
Trial: 18841784
Drug: Qinlian capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qinlian capsule for 7 days
Trial: 10503854
Drug: High volume
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High volume hydration (16-17 mL/kg)
Trial: 10503854
Drug: Low volume
RxNorm normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low volume hydration (1-2 mL/kg)
Trial: 8983875
Drug: Amino acids
RxNorm normalized name: Amino acids
DrugBank: Amino acids (DB09393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acids infusion
Trial: 1901635
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of angiotensin II (AII)
Trial: 1901635
Drug: AII infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AII infusion
Trial: 6292013
Drug: Naloxone (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.4 mg/min) infusion for 5 minutes before and 20 minutes after intravenous glucose (0.5 g/kg body weight)
Trial: 31944628
Drug: SZC 5
RxNorm normalized name: Sildenafil citrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SZC 5 g once-daily during maintenance phase (MP)
Trial: 31944628
Drug: SZC 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SZC 10 g once-daily during maintenance phase (MP)
Trial: 28753179
Drug: Weekly intervention
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly intervention (10 sessions during 10 weeks) for MC group.
Trial: 28753179
Drug: Both therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both therapy protocols (operant conditioning and systematic desensitization).
Trial: 16215308
Drug: Diethylstilboestrol (DES)
RxNorm normalized name: Diethylstilbestrol
DrugBank: Diethylstilbestrol (DB00255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diethylstilboestrol (DES) 1 mg/day with 75 mg of aspirin
Trial: 11498451
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg daily for 1 month)
Trial: 9778008
Drug: Deep cervical
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep cervical plexus block with 20 ml bupivacaine, 0.375%
Trial: 9778008
Drug: Superficial cervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superficial cervical plexus block with 20 ml bupivacaine, 0.375%
Trial: 8164824
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg dexamethasone per day
Trial: 8164824
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg dexamethasone per day
Trial: 8164824
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg dexamethasone per day
Trial: 3408828
Drug: Epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injection of 80 mg methylprednisolone in 10 ml physiological saline
Trial: 3408828
Drug: Interspinous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interspinous injection of 2 ml physiological saline
Trial: 31353217
Drug: Intermittent Preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Preventive Treatment (IPT) with dihydroartemisinin-piperaquine (4 and 18 mg/kg per day)
Trial: 31353217
Drug: Intermittent Screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Screening and Treatment (IST) with monthly malaria rapid diagnostic tests
Trial: 31353217
Drug: Single Screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Screening and Treatment (SST)
Trial: 24266552
Drug: Active analgesic
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active analgesic strategy with pre-medication with oral midazolam mixture and intravenous alfentanil and midazolam regularly administered during the procedure
Trial: 24266552
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with morphine and diazepam (control group)
Trial: 15488867
Drug: Decrease in
RxNorm normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decrease in triglycerides (n=19, median: -18 mg/dl)
Trial: 15488867
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in triglycerides (n=20, median: +44 mg/dl)
Trial: 11125269
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% dexamethasone solution
Trial: 27871603
Drug: Prophylactic infusion
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic infusion of phenylephrine (100-μg/mL solution at 1 mL/min)
Trial: 27871603
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0.9% isotonic sodium chloride solution)
Trial: 24150200
Drug: Ca+MZn+D group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca+MZn+D group (zinc, 15 mg/day + multivitamins; calcium, 500 mg/day; vitamin D, 30,000 IU/3 months)
Trial: 24150200
Drug: Ca+D group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ca+D group (calcium, 500 mg/day; vitamin D, 30,000 IU/3 months)
Trial: 22486143
Drug: Dexamethasone 0.5
RxNorm normalized name: dexamethasone 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.5 mg/kg i.v. and Ketamine 0.5 mg/kg i.v. (Group KD)
Trial: 22486143
Drug: Dexamethasone 0.5
RxNorm normalized name: dexamethasone 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.5 mg/kg i.v. (Group D)
Trial: 22486143
Drug: Ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5 mg/kg i.v. (Group K)
Trial: 20649409
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin (6 biannual mass distributions)
Trial: 19011472
Drug: High-dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methylprednisolone (HDMP) therapy (30 mg/kg/d for 3 d then 20 mg/kg/d for 4 d)
Trial: 19011472
Drug: High-dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methylprednisolone (HDMP) therapy
Trial: 15738450
Drug: Special intervention
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special intervention group (nutrition counseling, smoking cessation, increased physical activity, intensive blood pressure treatment)
Trial: 3786346
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 mg nicotine gum)
Trial: 23837461
Drug: Zonisamide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide (1 mg/kg/day titrated to 8 mg/kg/day over 8 weeks, maintained for 12 weeks)
Trial: 17488363
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (RSG) 4 mg twice daily for 6 weeks
Trial: 11354518
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of temazepam
Trial: 9059318
Drug: Mechanical oesophageal
RxNorm normalized name: PIPERONYL BUTOXIDE TECHNICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical oesophageal stimulation (0.5 s, 14 ml, 0.2 Hz)
Trial: 23435159
Drug: Basal plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal plus regimen with glargine once daily and supplemental doses of glulisine
Trial: 19123335
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment and nursing (Control)
Trial: 16095766
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of SsWC on Days 0, 14, and 28 (N = 3)
Trial: 16095766
Drug: Five doses
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five doses of SsWC on Days 0, 2, 4, 6, and 28 (N = 4)
Trial: 16095766
Drug: Both dosing
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosing regimens of SsWC
Trial: 12912816
Drug: Carvedilol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (25 mg single dose)
Trial: 12912816
Drug: Carvedilol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (25 mg BID for 6 months)
Trial: 12912816
Drug: Metoprolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (200 mg extended-release daily for 6 months)
Trial: 10792115
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg o.d.)
Trial: 8852907
Drug: Trivalent oral
RxNorm normalized name: poliovirus vaccine, live, trivalent oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent oral polio vaccine (OPV)
Trial: 2060435
Drug: d-fenfluramine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-fenfluramine (15 mg/day for 1 week)
Trial: 27790756
Drug: Adapalene 0.1%/benzoyl
RxNorm normalized name: ADAPALENE 0.1%/BENZOYL PEROXIDE 2.5% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1%/benzoyl peroxide 2.5% gel (A/BPO)
Trial: 17385938
Drug: Drospirenone in
RxNorm normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drospirenone in combination with estrogen
Trial: 17385938
Drug: Oral progestogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral progestogen preparations (control)
Trial: 15735107
Drug: Daily multiple
RxNorm normalized name: Daily Multiple Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily multiple micronutrient (DMM) supplement
Trial: 15735107
Drug: Weekly multiple
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly multiple micronutrient (WMM) supplement
Trial: 15735107
Drug: Daily iron
RxNorm normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron (DI) supplements
Trial: 8846749
Drug: L-propionyl carnitine
RxNorm normalized name: glycine propionyl-L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-propionyl carnitine (2 g by slow infusion b.i.d, plus heparin and buflomedil)
Trial: 8846749
Drug: Placebo (plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (plus heparin and buflomedil)
Trial: 2361811
Drug: Long duration
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long duration exercise (L‐EX)
Trial: 389824
Drug: Bacampicillin 400
RxNorm normalized name: bacampicillin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacampicillin 400 mg plus 1 g probenecid
Trial: 389824
Drug: Bacampicillin 800
RxNorm normalized name: bacampicillin 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacampicillin 800 mg plus 1 g probenecid
Trial: 389824
Drug: Bacampicillin 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacampicillin 1600 mg plus 1 g probenecid
Trial: 26187147
Drug: Active rTMS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active rTMS treatment (10Hz for 3 weeks)
Trial: 12630982
Drug: Clozapine treatment
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine treatment (n = 54)
Trial: 10715931
Drug: Power toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Power toothbrush (Braun Oral‐B Ultra Plaque Remover, Braun GmbH)
Trial: 1529284
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (10 g/day)
Trial: 2868467
Drug: Prophylactic maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic maintenance medication
Trial: 29394018
Drug: C‐T (cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C‐T (cream applied with repeated toner every 2 h)
Trial: 29394018
Drug: C+T (cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C+T (cream and toner applied successively)
Trial: 29394018
Drug: T+C (toner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T+C (toner and cream applied successively)
Trial: 29394018
Drug: C (cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C (cream only)
Trial: 29394018
Drug: C‐S (cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C‐S (cream applied with repeated spray water every 2 h)
Trial: 23033520
Drug: HIV antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV antibody test
Trial: 18089865
Drug: Gemcitabine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine infusion over 100 minutes
Trial: 18089865
Drug: Gemcitabine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine infusion over 30 minutes
Trial: 9702852
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of digoxin alone (Phase 1)
Trial: 9702852
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of digoxin after 200 mg of acarbose (Phase 2)
Trial: 9702852
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of digoxin after 100 mg of acarbose (Phase 3)
Trial: 2657105
Drug: Yohimbine hydrochloride
RxNorm normalized name: Yohimbine Hydrochloride
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine hydrochloride (maximum of 42.0 mg orally daily)
Trial: 4938431
Drug: Levodopa (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (maximum tolerated dosage)
Trial: 4938431
Drug: Levodopa +
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa + L-alpha-methyldopahydrazine
Trial: 29847672
Drug: PF-04634817 200
RxNorm normalized name: acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PF-04634817 200 mg once-daily (QD) plus placebo
Trial: 29847672
Drug: Ranibizumab 0.3/0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab 0.3/0.5 mg monthly plus oral placebo
Trial: 23104718
Drug: Oral care
RxNorm normalized name: Oral Care Q4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral care education
Trial: 15176768
Drug: Hallucination focused
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hallucination focused integrative treatment (HIT)
Trial: 9806657
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with carboplatin (600 mg/m2 on Day 1), cyclophosphamide (250 mg/m2 on Day 1), and cisplatin (100 mg/m2 on Day 8 every 4 weeks) with or without amifostine (740‐1140 mg/m2)
Trial: 9806657
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with carboplatin, cyclophosphamide, and cisplatin
Trial: 2679048
Drug: Nifedipine (10-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10-30 mg before meals)
Trial: 18371107
Drug: COPAD chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COPAD chemotherapy (cyclophosphamide, vincristine, prednisolone, and doxorubicin), given in two courses without intrathecal chemotherapy.